Authors: Malone B, Campbell EA

PMID: 34518697 DOI: 10.1038/s41594-021-00657-8

Abstract

Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication and prevents viral propagation by fostering error accumulation in a process referred to as ‘error catastrophe’.

Keywords: molnupiravir

Source: https://www.nature.com/articles/s41594-021-00657-8#:~:text=Molnupiravir%2C%20a%20wide%2Dspectrum%20antiviral,known%20as%20’lethal%20mutagenesis’.
Archive: https://archive.is/tCLOc

More on: I-CARE Early Covid | I-CARE Flu and RSV

More on: molnupiravir